AIDOT (CEO Jung Jae-hoon) announced on July 6 that it has obtained regulatory approval registration from AGEMED, Bolivia’s national authority responsible for the registration of pharmaceuticals and medical devices.
Bolivia is widely regarded as one of the most severely affected countries in Latin America for cervical cancer. Out of 4.01 million women aged 15 and older, Bolivia reports approximately 1,986 new cervical cancer cases and 1,054 deaths annually—an estimated 53% fatality rate. The incidence is reported at 36.6 cases per 100,000 people, and cervical cancer ranks No. 1 among cancers affecting Bolivian women.
The approval was granted by AGEMED, the Bolivian institution that oversees medical regulatory approvals and enforcement across the healthcare sector. AGEMED is responsible for verifying and regulating the quality and safety of pharmaceuticals and medical devices and plays a key role in protecting public health in Bolivia.
An AIDOT global sales and marketing representative said that this approval enables the company to formally enter Bolivia and establish a foundation for expansion into the broader
Central and South American market. The company added that it is actively communicating with partners in Brazil, Argentina, and neighboring Latin American countries, and expects additional growth opportunities. The representative also noted that the company is pleased to help provide a more efficient environment for cervical cancer screening in Bolivia, where cervical cancer is the leading cause of cancer-related deaths among women.
AIDOT stated that it has continued to pursue overseas regulatory registrations since last year, building recognition for reliability and quality in the medical device industry—an outcome it attributes to its product lineup and stringent quality management systems.
The company added that it will continue R&D and innovation to further establish itself as a company that commercializes medical AI solutions in real-world overseas healthcare settings.
July 6, 2023 / Korea Economic TV / Reporter Park Jun-sik
